PsABiostudy followed PsA pts starting TNFi vs ustekinumab x12 mos showing equivalent durability at 1 yr (72% vs 71%). cD
Tweet Content
PsABiostudy followed PsA pts starting TNFi vs ustekinumab x12 mos showing equivalent durability at 1 yr (72% vs 71%). cDAPSA LDA was seen in 56% UST vs 67% TNFi (similar for MDA (34% vs 43%) https://t.co/briK7itZtL https://t.co/Rq1SXA7s1s
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off